Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital

The effect of hydroxychloroquine on haemostasis, complement, inflammation and angiogenesis in patients with antiphospholipid antibodies

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Functional neuroimaging of recovery from motor conversion disorder: A case report

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Prevalence and significance of anti-phosphatidylserine antibodies: A pooled analysis in 5992 patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Clinical utility of anti-MOG antibody testing in a Danish cohort

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Karen Schreiber
  • Karen Breen
  • Kiran Parmar
  • Jacob H Rand
  • Xiao-Xuan Wu
  • Beverley J Hunt
View graph of relations

Objectives: HCQ has been described as having a beneficial effect in patients with APS but its mechanism of action is unclear. We hypothesized that HCQ may have effects on subnormal angiogenesis, inflammation and haemostatic biomarkers seen in APS. The aim of our study was to assess laboratory markers [annexin A5 (AnxA5) anticoagulant activity, tissue factor (TF) levels, thromboelastography (TEG), CRP, Bb, C3a and VEGF] in HCQ-naïve patients with aPL at baseline and after commencing HCQ.

Methods: Twenty-two patients with aPL [20 female, 2 male, median age 55 (range 18-70) years] had blood taken pre- and 3 months after starting HCQ 200 mg daily.

Results: Soluble TF levels were significantly reduced comparing baseline and 3 months after HCQ commencement [401.8 (152.8) vs 300.9 (108) pg/ml (P = 0.010)]. No significant changes were found in the following [reported as pre- and post-HCQ commencement, mean (s.d.)]: AnxA5 anticoagulant ratio [187.1 (29.5) vs 193 (31) (P = 0.157)], anti-domain1 β2 glycoprotein1 IgG activity [1.8 (2) vs 1.2 (1.4) μg/ml (P = 0.105)], complement C3a-des-Arg [147.8 (84.5) vs 154.4 (88.1) ng/ml (P = 0.905)], complement Bb [1.3 (0.7) vs 1.1 (0.7) μg/ml (P = 0.422)], VEGF [68.8 (40) vs 59.4 (19.6) pg/ml (P = 0.454)] and CRP [7 (3.5) vs 7 (3.9) μg/ml (P = 0.917)]. TEG results including TEG reaction time, achievement of clot firmness, TEG maximum amplitude and TEG percentage lysis 30 and 60 min after maximum amplitude showed no significant difference.

Conclusion: HCQ significantly reduced soluble TF levels in patients with aPL. No significant change was observed in AnxA5 activity, anti-domain 1 IgG activity, TEG, CRP, complement Bb and C3a-des-Arg, and VEGF. Further studies of a larger patient cohort are needed.

Original languageEnglish
JournalRheumatology (Oxford, England)
Issue number1
Pages (from-to)120-124
Number of pages5
Publication statusPublished - 1 Jan 2018

    Research areas

  • Adolescent, Adult, Aged, Annexin A5/metabolism, Antibodies, Antinuclear/immunology, Antibodies, Antiphospholipid/immunology, Antiphospholipid Syndrome/drug therapy, Antirheumatic Agents/therapeutic use, C-Reactive Protein/metabolism, Complement C3a/immunology, Complement System Proteins/immunology, Hemostasis, Humans, Hydroxychloroquine/therapeutic use, Immunoglobulin G/immunology, Middle Aged, Neovascularization, Physiologic, Prospective Studies, Thrombelastography, Thromboplastin/metabolism, Treatment Outcome, Vascular Endothelial Growth Factor A/metabolism, Young Adult, beta 2-Glycoprotein I/immunology

ID: 56683860